Reuter U, et al. Long-term efficacy and safety of erenumab: Results from 64 weeks of the LIBERTY study. IHC-OR-006. IHC 2019 5-8 sept. Dublin, Ierland.
Onderzoek geeft inzicht in stadia cerebrale amyloïdangiopathie
aug 2023 | Dementie, Neuro-vasculair